Carcinoma, Non-Small-Cell Lung Clinical Trials in Tampa, Florida

5 studies are recruiting for carcinoma, non-small-cell lung in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective th…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    369 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06890598 on ClinicalTrials.gov

  2. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C m…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Local Institution - 0647, Tampa, Florida
    Locations
    351 in total
    Run by
    Mirati Therapeutics Inc.

    See if you can join NCT06875310 on ClinicalTrials.gov

  3. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

    The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characteriz…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    H. Lee Moffitt Cancer & Research Institute, Tampa, Florida
    Locations
    110 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT05498428 on ClinicalTrials.gov

  4. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    203 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT06667076 on ClinicalTrials.gov

  5. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Florida Cancer Specialists, Tampa, Florida
    Locations
    440 in total
    Run by
    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.